性别对主髂动脉闭塞性疾病血运重建结局的影响
该回顾性队列研究纳入2017年1月至2024年1月因主髂动脉闭塞性疾病行腔内治疗的连续患者,比较女性和男性患者的通畅率、保肢率、再干预率和生存率。共108例尝试腔内手术,技术成功103例(95.4%),女性57例(55.3%),男性46例(44.7%)。结果显示男女患者在通畅率、保肢率、总体生存率和免于靶病变再干预方面结局相似;覆膜支架与裸金属支架相比与更高的一期通畅率和更低再干预率相关,同期股总动脉内膜剥脱术是一期通畅率的保护因素。
要点
- 男女患者在主髂动脉腔内治疗后的通畅率、保肢率和生存率相似。
- 覆膜支架使用与更高一期通畅率和更低再干预率相关。
- 同期股总动脉内膜剥脱术是一期通畅率的保护因素。
核心结论
- 女性和男性主髂动脉闭塞性疾病患者接受腔内治疗后的通畅率、保肢率、总体生存率和免于靶病变再干预率相似。
- 覆膜支架与裸金属支架相比与更高的一期通畅率和更低再干预率相关。
- 同期股总动脉内膜剥脱术是一期通畅率的保护因素。
研究设计与样本
- 回顾性队列研究,使用前瞻性收集的数据,纳入2017年1月至2024年1月因主髂动脉闭塞性疾病行主髂动脉血管成形术的连续患者。
- 共108例尝试腔内手术,技术成功103例(95.4%),纳入研究队列;女性57例(55.3%),男性46例(44.7%)。
- 纳入标准为危及肢体的严重缺血或致残性间歇性跛行;采用Cox回归分析与一期通畅率、大截肢和总体生存相关的因素。
主要发现
- 动脉性高血压是最常见的合并症(79.6%),女性组高于男性组(87.7% vs. 69.6%,P = 0.021);血脂异常63.1%,糖尿病54.4%,缺血性心脏病28.2%,男性组高于女性组(65.3% vs. 34.5%,P = 0.005)。
- 同期股总动脉内膜剥脱术11例(10.7%;男性组13%,女性组8.8%;P = 0.48)。
- 围手术期死亡率为11.7%,组间无显著差异(P = 0.82)。
- 1000天一期通畅率男性组80.1%,女性组78.1%(P = 0.43);1000天保肢率男性组95.5%,女性组95.5%(P = 0.57)。
- Cox回归分析显示裸金属支架使用是一期通畅率降低的预测因素(HR 15.99,95% CI 2.07-122.996;P = 0.008),而股总动脉内膜剥脱术是一期通畅率更好的保护因素(HR 0.123,95% CI 0.020-0.778;P = 0.026)。
关键数值与推荐
- 技术成功定义为103例(95.4%)成功完成腔内手术。
- 一期通畅率降低的预测因素:裸金属支架使用(HR 15.99,95% CI 2.07-122.996;P = 0.008)。
- 一期通畅率更好的保护因素:同期股总动脉内膜剥脱术(HR 0.123,95% CI 0.020-0.778;P = 0.026)。
临床怎么用
- 在主髂动脉闭塞性疾病腔内治疗中,性别不应作为选择治疗方式的决定性因素,因男女结局相似。
- 优先考虑使用覆膜支架而非裸金属支架,以改善一期通畅率并降低再干预率。
- 对于合适患者,同期行股总动脉内膜剥脱术可能改善一期通畅率。
局限性
- 回顾性队列研究设计可能引入选择偏倚。
- 样本量较小(103例),可能影响统计效能。
- 研究为单中心数据,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of the present study was to assess the impact of gender on outcomes following endovascular treatment of AIOD, focusing on patency, limb salvage, reintervention rates, and survival. METHODS: This retrospective cohort study of prospectively collected data included consecutive patients with AIOD who underwent aortoiliac angioplasty between January 2017 and January 2024. Two groups were analyzed: (1) female patients, (2) male patients. Eligible patients presented with critical limb-threatening ischemia or disabling claudication. Regression cox was performed to evaluate the factors related to primary patency, major amputation, and overall survival. Among several factors analyzed, covered versus bare-metal stents and common femoral endarterectomy were evaluated. RESULTS: A total of 108 endovascular procedures were attempted. Technical success was achieved in 103 patients (95.4%), who comprised the study cohort. The female group predominated with 57 patients (55.3%) and the male group with 46 patients (44.7%). Arterial hypertension was the most prevalent comorbidity (79.6%), with higher prevalence at female group than male group (87.7% vs. 69.6%, P = 0.021), followed by dyslipidemia (63.1%), diabetes mellitus (54.4%), and ischemic heart disease (28.2%), with higher prevalence at male group than female group (65.3% vs. 34.5%, P = 0.005). Concomitant common femoral endarterectomy (CFE) was performed in 11 patients (10.7%; 13% male group and 8.8% female group; P = 0.48). The perioperative mortality rate was 11.7%, with no significant differences among groups (P = 0.82). Primary patency at 1,000 days was 80.1% at male group and 78.1% at female group (P = 0.43). Limb salvage rates at 1000 days were 95.5% at male group and 95.5% at female group, P = 0.57. Cox regression analysis identified bare-metal stent use as a predictor of reduced primary patency (HR 15.99, 95% CI 2.07-122.996; P = 0.008). Conversely, CFE was a protective factor for better primary patency (HR 0.123, 95% CI 0.020-0.778; P = 0.026). CONCLUSION: In conclusion, female and male patients with AIOD submitted to endovascular treatment had similar outcomes regarding patency, limb salvage rates, overall survival, and freedom from target-lesion reintervention. Moreover, covered stent use was associated with higher primary patency and lower reintervention rates compared with bare-metal stents, and concomitant CFE was a protective factor for better primary patency.
引用
- de Athayde Soares R, Lorenzoni GS, Pinheiro VG, et al. The Influence of Gender on the Outcomes of Revascularization for Aortoiliac Occlusive Disease. Ann Vasc Surg. 2026. PMID: 41903846. doi:10.1016/j.avsg.2026.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。